Selamat datang di ForSa! Forum diskusi seputar sains, teknologi dan pendidikan Indonesia.

Welcome to Forum Sains Indonesia. Please login or sign up.

Maret 28, 2024, 09:15:29 PM

Login with username, password and session length

Topik Baru

Artikel Sains

Anggota
Stats
  • Total Tulisan: 139,653
  • Total Topik: 10,405
  • Online today: 116
  • Online ever: 1,582
  • (Desember 22, 2022, 06:39:12 AM)
Pengguna Online
Users: 0
Guests: 95
Total: 95

Aku Cinta ForSa

ForSa on FB ForSa on Twitter

multiple skelerosis

Dimulai oleh khenstein, Maret 25, 2011, 12:03:05 AM

« sebelumnya - berikutnya »

0 Anggota dan 1 Pengunjung sedang melihat topik ini.

khenstein

ada yang tau???????

terus kalo peradangan otak stadium akhir persentase hidup berapa persen????
apa obat nya????? sama kalo gak operasi bertahan berapa lamaa... tolong yang berilmu disini saya minta wejangan nya
hampa itu isi dan isi itu hampa

Astrawinata G

peradangan otaknya karena apa? infeksi? autoimun? trus kok ada stadiumnya? ??? ane baru tau....
Best Regards,


Astrawinata G

khenstein

yah saya juga gak tau... dokter yang bilang bgtu keteman saya..... gak tau cuma diwilayah jaring laba2 atau apa itu namya??? yang antara tengkorak sama otak... itu ada peradangan............ autoimun apa yah????
saya juga bingung bukan nya kalo stadium berarti kanker....
hampa itu isi dan isi itu hampa

syx

#3
di otak ada jaring laba-labanya? wah akibat udah lama ga dipake kali...

autoimun itu sakit yang dipicu oleh ketidakmampuan sistem imun kita dalam mengenali siapa lawan dan siapa kawan. jadi badan sendiri yang diserang.

Astrawinata G

antara otak dengan tengkoraknya meradang? apa jangan2 meningitis? tapi saya juga ga tau apa ada stadiumnya atau tidak :(

kalau stadium, ga cuma kanker kok, banyak penyakit yang juga punya grade (stadium)
Best Regards,


Astrawinata G

Huriah M Putra

Jadi multiple sclerosis itu apa dok?
[move]OOT OOT OOT..!!![/move]

khenstein

kalo multiple sclerosis itu penyakit yang menggrogoti sistem motorik pasien nya kan..... kayak kartunis indonesia itu siapa yah nama nya lupa lagi saya??
dok kalo meningitis ngobati nya sampai pake operasi gak?????
hem ciri2 orang yang terkena gimna??? soal nya temen saya kalo mikir terlalu serius dikit langsung puyeng n mimisan
hampa itu isi dan isi itu hampa

syx

Kutip dari: khenstein pada Maret 26, 2011, 11:26:30 PM
... soal nya temen saya kalo mikir terlalu serius dikit langsung puyeng n mimisan
musti ditanya tuh mikir apaan... jangan-jangan seperti ini:
Sorry but you are not allowed to view spoiler contents.

khenstein

jiah bukan kali, dia kan cew..... kalo ada masalah gtu maksud nya..... jiah om syx nih kali yang sering bgtu.... gak boleh yah ntar dimarahin bapak nya
hampa itu isi dan isi itu hampa

Astrawinata G

Kutip dari: Huriah M Putra pada Maret 25, 2011, 06:14:59 PM
Jadi multiple sclerosis itu apa dok?
wah, saya belum dokter Prof, masih dibawah kaki prof nih, lupa?hehehe....
MS sih peradangan juga, dan ada stagingnya berdsarkan klinis pasien...ada 20 staging mulai dari 0 sampai 10 dengan kenaikan 0,5 tiap staging (wah, baru tau nih :()

buat Mas Khen: kata dokter yang merawat kawan Mas, dia kena penyakit apa? radang otak? ada info lebih?
Best Regards,


Astrawinata G

khenstein

yah masalah nya itu, saya blom pernah barengan dengan dia k rumah sakit,,, lagian saya terpisah pulau dengan dia.... saya bertemu dengan nya setahun sekali..... setahun kemaren dia itu katanya udah stadium 2..... waktu saya ketahui itupun kakak nya yang cerita...... ada yang mengerti???
hampa itu isi dan isi itu hampa

syx

Emerging Therapies in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) with presumed inflammatory and degenerative elements. MS entered the rather small ranks of neurologic diseases with disease-modifying therapies in 1993. Since then, 6 agents have received regulatory approval. Five of these agents are indicated for treatment of the relapsing forms of MS and 1 agent for more severe, worsening forms. No therapy is approved or has shown efficacy in treating primary progressive MS. All of the currently available agents are immunomodulatory, strongly supporting the evidence that the pathogenesis of MS relates to an immune aberration. MS has much in common with autoimmune diseases of other organs; although there are abundant data supporting a dysimmune state in patients with MS, the proof of autoimmunity is not yet available. The successful employment of immunomodulating therapies also raises questions about the potential role of other putative causes for MS. Although it had been hoped that increased knowledge of the immunopathogenesis of MS would lead to more focused therapies, that goal has only been partially realized.

The first-line therapeutic agents include glatiramer acetate and 3 versions of interferon beta: 2 regimens of beta-1a and 1 regimen of beta-1b. All are administered parenterally (intramuscularly or subcutaneously) by injection from once weekly to daily. In addition to demonstrated efficacy in relapsing-remitting MS, these agents are efficacious when employed after a first attack of demyelination, before a secure diagnosis of MS can be made. Interferon has several potential mechanisms of action that could be at work in treating MS. These include shoring up the blood-brain barrier, an antiproliferative effect on lymphocytes, downregulation of helper T-cell functions, antagonizing interferon gamma, and shifting of immune function from helper mode to regulatory mode. Glatiramer acetate is thought to act primarily by shifting the immune system from helper to regulatory functions through generation of glatiramer acetate-reactive T cells. It also has effects on other immune elements and potential neuroprotective actions.[1]

Second-line agents include natalizumab, which has demonstrated excellent efficacy in relapsing-remitting MS, but because of a more challenged safety profile compared with the first-line agents, it is usually employed after failure of the first-line agents. Natalizumab is a monoclonal antibody directed against the adhesion molecule VLA-4.

Blockade of VLA-4 limits the egress of lymphocytes from the bloodstream into the CNS. In clinical trials of early MS, natalizumab demonstrated significant improvement in reducing relapse rate and accrual of disability.[2] Natalizumab was also effective in treating individuals with evidence of disease activity while on low-dose interferon.[3] Natalizumab is associated with development of progressive multifocal leukoencephalopathy, a viral infection of the brain, the risk of which increases with time on the therapy.[4] Mitoxantrone, a chemotherapeutic agent is also used second line, especially in those who transition to secondary progressive MS. Mitoxantrone is broadly immunosuppressive of all immune elements.[5] As a chemotherapeutic agent, mitoxantrone has a number of significant toxicities. Both of these agents are administered by intravenous infusion.

All of these agents are partially effective. Head-to-head studies have suggested that higher doses of interferon are more effective than lower doses, and that higher-dose interferon and glatiramer acetate have equivalent clinical efficacy.[6,7] Although natalizumab has impressive efficacy data, there are no head-to-head studies comparing it with the first-line therapies.

The current therapeutic needs in relapsing-remitting MS are for more effective, safer, and easier-to-administer agents that will treat all forms of MS. This review explores how none of the pipeline agents are likely to fulfill all 3 of these criteria. Therefore, the pipeline is quite full with new and interesting molecules that have the potential to enhance our ability to treat this illness.

syx

... lanjutan artikel di atas cuma kondisi terkini obat-obat baru yang masih dalam uji klinis. jadi ga perlu dibahas dulu.

khenstein

WADUH BAHAYA BERARTI NIH BARU UJI KLINIS... APA PENYAKIT LANGKA ATAU BARU YAH KATEGORI INI
hampa itu isi dan isi itu hampa